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Abstract
Background: Accumulation of filamentous a-synuclein as Lewy bodies is a hallmark of Parkinson’s disease. To
identify the mechanisms involved in a-synuclein assembly and determine whether the assemblies are cytotoxic, we
developed a cell model (3D5) that inducibly expresses wild-type human a-synuclein and forms inclusions that
reproduce many morphological and biochemical characteristics of Lewy bodies. In the present study, we evaluated
the effects of several histone deacetylase inhibitors on a-synuclein aggregation in 3D5 cells and primary neuronal
cultures. These drugs have been demonstrated to protect cells transiently overexpressing a-synuclein from its
toxicity.
Results: Contrary to transient transfectants, the drug treatment did not benefit 3D5 cells and primary cultures. The
treated were less viable and contained more a-synuclein oligomers, active caspases 3 and 9, as well as ER stress
markers than non-treated counterparts. The drug-treated, induced-3D5 cells, or primary cultures from transgenic
mice overexpressing (<2 fold) a-synuclein, displayed more a-synuclein oligomers and ER stress markers than non-
induced or non-transgenic counterparts. Similar effects were demonstrated in cultures treated with tunicamycin, an
ER stressor. These effects were blocked by co-treatment with salubrinal, an ER stress inhibitor. In comparison, co-
treatment with a pan caspase inhibitor protected cells from demise but did not reduce a-synuclein oligomer
accumulation.
Conclusions: Our results indicate that an increase of wild-type a-synuclein can elicit ER stress response and
sensitize cells to further insults. Most importantly, an increase of ER stress response can promote the aggregation
of wild type a-synuclein.
Background
Parkinson’s disease (PD) and related disorders known as
synucleinopathies are characterized by abnormal accu-
mulation of a-synuclein (a-Syn). Such filamentous
aggregates in neuronal perikarya and processes are
referred to as Lewy bodies and Lewy neurites, respec-
tively [1,2]. Most synucleinopathies are sporadic, but
some are linked to missense mutation or multiplications
of the gene encoding a-Syn [3-8].
In order to understand how and why a-Syn accumula-
tion affects neuronal survival, several experimental mod-
els have been generated. In some cell-based studies
overexpression of a-Syn did not affect cell survival but
sensitized the cultures (mutant a-Syn in particular) to
insults [9,10]. In others, the results were different.
Infection of primary mesencephalic neuronal cultures
with lentiviral constructs containing A53T mutant a-
Syn led to reduced cell viability [11]. Transient co-
expression of mutant a-Syn and synphilin-1 in H4 cells
was reported to cause formation of cytoplasmic a-Syn
inclusions and cytotoxicity. These changes were alle-
viated by treatment with Agk2, a histone deacetylase
(HDAC) inhibitor [11]. Transient expression of wild-
type a-Syn in the nuclei of SH-SY5Y cells, but not cyto-
plasm, was reported to cause a-Syn aggregation and
cytoxicity that can be prevented by a 48-hour (h) treat-
ment with 10 mM sodium butyrate (SB) [12]. It remains
unknown whether benefits comparable to those
observed in transient transfectants are attainable in
stable transfectants overexpressing a-Syn and whether
comparable outcomes can be achieved with exposure to
o t h e rH D A Ci n h i b i t o r s ,s i n c e there are multiple classes
of HDAC. Some of these issues were examined in the
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any medium, provided the original work is properly cited.present studies using cell cultures, referred to as 3D5, of
human neuroblastoma BE2-M17D cells overexpressing
wild-type human a-Syn [13]. The overexpression of
human a-Syn in 3D5 cultures is regulated by the tetra-
cycline-off (TetOff) inducible mechanism. These cells
develop neuritic processes and express neuronal markers
in response to all-trans-retinoic acid (RA) treatment
[14]. 3D5 cells that have been treated with RA for 10
days (ds) followed by 28 ds of induced a-Syn expression
are capable of forming a-Syn inclusions that reproduce
many morphological and biochemical characteristics of
Lewy bodies [14]. Similar a-Syn inclusions were not
readily detected in 3D5 cultures after 14 ds of induced
a-Syn expression, although the cultures were biochemi-
cally demonstrated to contain a-Syn oligomers.
It has been well documented that acetylation and dea-
cetylation of histone proteins play important roles in the
epigenetic regulation of transcription and other cellular
functions [15,16]. Deacetylation of histone proteins leads
to the silencing of gene expression. At least four major
classes of HDACs have been identified in mammalian
cells [17-21] and several HDAC inhibitors have been
developed. Some HDAC inhibitors are more specific to
certain subclasses of HDAC than others [17,18]. For
example, fatty acid derivatives such as sodium butyrate
(SB) and valproic acid (VPA) are capable of inhibiting
class I (HDAC8 in particular) and class II HDAC [22].
In comparison, Agk2 is more specific to sirtuin 2, a
member of class III HDAC [11].
In this study we used RA-differentiated 3D5 cultures,
with or without induced a-Syn expression, and evalu-
ated their responses to SB, VPA or Agk2 exposure. We
began with cultures that have 10 ds of induced a-Syn
expression. The goal was to establish background infor-
mation on the drug dosage and duration of treatment
and use the information in a subsequent cell-based
study with an extended duration (e.g 28 ds) of a-Syn
overexpression. We unexpectedly found that SB or
other HDAC inhibitors treatment of 3D5 cells with
induced a-Syn expression caused an increase of a-Syn
aggregate accumulation in a time- and dose-dependent
manner. Such changes were not detected in the SB-trea-
ted, non-induced cultures or in 3D5 cells treated with
sodium acetate (SA). More important, 3D5 cultures with
a-Syn induction were less viable than those without the
induction when exposed to HDAC inhibitors. Similar
results were obtained using primary neuronal cultures
generated from a-Syn transgenic (TG) mice and their
non-transgenic (NT) littermates. The TG mice express
wild-type human a-Syn at levels much lower than that
displayed by the TetOff induced 3D5 cultures. These
findings prompted us to examine whether a-Syn aggre-
gation is closely associated with apoptosis or upstream
pathways.
Results
SB exposure causes accumulation of a-Syn oligomers and
activation of caspase 3 in a dose- and time-dependent
manner
We exposed 3D5 cultures to between 2 and 20 mM SB
for 24 hrs and determined the effects of these exposures
on a-Syn oligomer accumulation. This drug is com-
monly used at a millimolar range and has been shown
to inhibit histone deacetylation in cell cultures at 2 mM
or higher concentrations [23]. Prior to the drug treat-
ment, 3D5 cultures were differentiated with RA and
induced to express a-Syn for 10 ds. Compared to non-
treated cultures, the drug treatment caused accumula-
tion of different sized (≥34 kDa) a-Syn oligomers in a
dose-dependent manner as demonstrated by Western
blotting using a-Syn antibodies Synuclein 1 (Figure 1A)
and Ab 98 (data not shown), which recognize different
epitopes. This increase in a-Syn oligomer levels was
accompanied by increased amounts of active caspase 3
(Figure 1A). We also analyzed cell lysates from cultures
treated with 10 mM SB for different durations. We
found that the levels of a-Syn oligomers and active cas-
pase 3 increased in a time-dependent manner (Figure
1B). Similar results were demonstrated in 3D5 cultures
Figure 1 Effects of sodium butyrate (SB) exposure on a-Syn
oligomerization and caspase 3 activation. 3D5 cells with 10 days
(ds) of RA-elicited differentiation and TetOff-induced a-Syn
expression were exposed to (A) 0, 2, 5, 10 or 20 mM SB for 24
hours (hs) and (B) 10 mM SB for 6, 12, 24 or 36 hs. Cultures without
SB treatment for 36 hs were used as controls (Con) for (B). Proteins
from the SB-treated and non-treated cultures were resolved by SDS-
PAGE and probed with antibodies to a-Syn, GAPDH and active
forms of caspase 3. The SB-treated cultures contained more a-Syn
oligomers (34 to 230 kDa in size) and cleaved caspase 3. The effect
of SB on a-Syn oligomerization and apoptosis is dose- and time-
dependent. Molecular weight markers shown in current and
subsequent figures were for determining the size of a-Syn products.
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Page 3 of 16exposed to VPA or Agk2 (Additional file 1). In contrast,
exposure of 3D5 cells to sodium acetate (SA, also a deri-
vative of short-chain fatty acid) did not increase a-Syn
oligomer accumulation (Additional file 2).
Cultures with SB exposure accumulate a-Syn oligomers
with different solubility
To characterize a-Syn oligomers further, we fractionated
total lysates (TL) from non-treated (control) and SB-
treated 3D5 cultures to generate buffer-soluble (SN1),
salt plus sarkosyl-extractable (SN2) and sarkosyl-insolu-
ble (SKI) samples and then analyzed using Western
blotting (Figure 2). All fractions from SB-treated cells
contained a-Syn oligomers (Figure 2), although the SKI
fraction displayed more large-sized oligomers, some of
which were retained at the top of separation gel. After
correction for differences in sample loading, the amount
of a-Syn oligomers recovered in SKI fraction was about
the same as that recovered in the SN2 or SN1 fraction.
In comparison, samples from non-treated cells con-
tained much less sarkosyl-insoluble a-Syn oligomers.
Morphological assessment of cultures and SKI samples
Immunocytochemistry
To determine whether SB exposure during a-Syn induc-
tion (a-Syn+) promotes accumulation of a-Syn aggre-
gates and subsequent fibrillogenesis, 3D5 cells were
subject to immunocytochemistry with a-Syn antibodies
and Thioflavin S staining. Many SB-treated cells dis-
played both a-Syn and Thioflavin positive inclusions
(Figure 3, SB-treated, marked by arrowheads), however,
such a labeling pattern was neither demonstrated in a-
Syn+ cultures without SB exposure nor in a-Syn-cul-
tures with SB treatment (Figure 3, Control).
Electron microscopy
The SB-treated a-Syn+ cells contained two groups of
filamentous structures, which appeared in clusters or
bundles (Figures. 4A-D). These filaments had a diameter
of either 8-10 nm or about 5 nm (Figures. 4B &4D), and
are far less abundant in a-Syn+ cultures without the SB
treatment (Figures. 4E &4F).
Immunoelectron microscopy
To determine whether SB exposure resulted in assembly
of filamentous a-Syn, we probed SKI samples prepared
from cultures with either a-Syn antibodies or without,
followed by secondary antibodies with immunogold
labeling and viewed at the ultrastructural level. Filamen-
tous elements of diameter 8-10 nm were detected in
samples from the SB-treated samples only, and they
often appear as small bundles (Figure 5A-C) positive for
a-Syn (Figure 5D, arrows marked immunogold labeled
filaments). In contrast, 5 nm filaments were not
detected in these samples by electron or immunoelec-
tron microscopy.
SB exposure does not affect the level of a-Syn in 3D5
cells with induced a-Syn expression
It has been reported that a major cellular effect of SB is
modulation of gene expression [15,16]. Therefore, the
accumulation of a-Syn oligomers in SB-treated 3D5 cul-
tures may be due to an increase of a-Syn expression.
This possibility was tested by comparing the amount of
total, monomeric and oligomeric a-Syn in the SB-trea-
ted and non-treated cultures, which had been subjected
to 10 ds of differentiation plus 9 ds of induced a-Syn
expression or 10 ds of differentiation plus 5ds of induc-
tion (started on the 5
th day of differentiation). By dot
blotting (Figure 6), we detected very few differences in
a-Syn expression between the 5 d-induced cultures with
and without SB treatment, but found higher levels of a-
Syn in the 9 d-induced cultures. Based on 3 independent
experiments, in which the ratio of a-Syn to GAPDH
was set to 1 for 5d-induced samples, the ratio is 0.97 ±
0.09 (average ± stand error of mean) and 1.58 ± 0.06,
for the 5d-induced with SB treatment and the 9-d
induced cultures, respectively. Statistical analysis
Figure 2 SB-treated cultures accumulate a-Syn of different
solubility and sizes. 3D5 cells were treated with 10 mM SB for 36
hs after 10 ds of differentiation and induced a-Syn expression.
Cultures without the drug treatment were used as controls (Con).
Total cell lysates (TL) were fractionated to obtain buffer-soluble
(SN1), buffer-insoluble and salt plus sarkosyl-soluble (SN2) as well as
sarkosyl-insoluble (SKI) fractions. These samples were evaluated by
immunoblotting using TL:SN1:SN2:SKI at 1:1:3.75:9.37 loading and
antibodies to a-Syn. GAPDH was used as loading control. Asterisk
marks monomeric a-Syn.
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between the 5d- and 9d-induced samples but no differ-
ence (P > 0.8) between the 5d-induced and its SB-trea-
ted counterpart. More a-Syn oligomers were observed
by Western blot in the 5 d-induced, SB-treated cultures
than the 9 d-induced, non-treated. The results indicate
that a 24-h exposure of 3D5 cells to SB does not affect
a-Syn levels, suggesting that other factors, besides a-
Syn expression, may be involved in the accumulation of
a-Syn oligomers in cultures with SB treatment.
To demonstrate further that SB treatment did not
affect oligomeric a-Syn accumulation via an increase
of a-Syn synthesis, we analyzed 3D5 cells that have
been exposed to SB, SB plus Tet (2 μg/ml, for block-
ing of a-Syn induction), SB plus cycloheximide
(CHX, 20 μM, for inhibition of protein synthesis),
CHX or Tet for 36 hs by Western blotting. The ana-
lysis showed the co-treated cultures contained only
slightly fewer a-Syn oligomers than those treated
with SB, but much more than those treated with
CHX or Tet (Additional file 3). The results support
the possibility that oligomer accumulation in SB-trea-
ted cells is unlikely caused by an increase of a-Syn
expression.
Figure 3 Accumulation of a-Syn and thioflavin-positive inclusions in SB-treated cultures. Retinoic acid-differentiated 3D5 cells with
induced a-Syn expression (a-Syn+) or without (a-Syn-) were treated with SB (10 mM) or without (control) for 36 hs, followed by a-Syn
immunofluorescence labeling and Thioflavin S staining. Alpha-Syn and Thioflavin S positive inclusions were detected only in the SB-treated
cultures (marked by arrowheads). Nuclei were marked with DAPI stain. About 50% of cells with a-Syn expression and SB treatment contained
aggregated a-Syn, and at the least 40% of such aggregates were Thioflavin S positive. Scale bar: 20 μm
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Page 5 of 16Figure 4 Electron micrographs of cultures with and without drug treatment. (A-D) Exposure to SB (10 mM) for 36 hs resulted in
accumulation of filamentous aggregates in differentiated 3D5 cells with induced a-Syn expression. (E-F) Without the SB treatment very few
filamentous elements were detected in differentiated 3D5 cells with induced a-Syn expression. (B), (D) and (F) are higher magnification
photographs of the framed area shown in (A), (C) and (E), respectively. The filaments have a diameter of either (B) 8-10 nm or (D) around 5 nm.
Scale bar: 0.5 μm (A, C and E); 100 nm (B, D and F).
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oligomer accumulation
To determine the effect of SB treatment on cell viability,
we treated subsets of differentiated and induced 3D5 cul-
tures with SB or SB plus a pan caspase inhibitor (CI). Cul-
tures without any drug treatment or treated only with CI
were included as controls. The SB exposure caused a sig-
nificant decrease in cell viability (Figure 7A). Such effect
was significantly attenuated in cultures co-treated with CI,
indicating a role for apoptosis in SB cytotoxicity. Treat-
ment of cultures with CI alone did not affect their viability.
We next determined whether the SB-treated cultures
differed from non-treated in terms of apoptosis and
whether apoptosis per se is responsible for accumulation
of a-Syn oligomers (Figure 7B). The SB-treated cultures
were found to contain far more active forms of capases
3, caspase 9 and cleaved PARP than the non-treated,
indicating the treated underwent apoptosis. In cells co-
treated with SB and CI, the amount of both active
capases 3 and 9 was reduced, whereas the level of a-Syn
oligomers was not, indicating a-Syn aggregation is likely
an upstream event of caspase activation.
Exposure of a-Syn overexpressing 3D5 cultures to SB or
other HDAC inhibitors induces ER stress response leading
to accumulation of a-Syn oligomers and apoptosis
Exposure to HDAC inhibitors such as SB has been
reported to cause not only apoptosis, but also lipid
peroxidation [24], oxidative stress [24-27], mitochondrial
dysfunction [28,29] and ER stress [30-32]. Since accu-
mulation of a-Syn oligomers in 3D5 cells was not
blocked by treatment with pan caspase inhibitor, we
decided to test whether it can be reduced by treatment
with inhibitors capable of blocking several upstream
events leading to caspase activation. Cell cultures were
treated with SB or co-treated with different dosages/
Figure 5 Ultrastructural evaluation of sarkosyl-insoluble
preparations from cell cultures. (A-C) Sarkosyl-insoluble samples
from SB-treated 3D5 cells depicted in Fig. 2 were adsorbed on EM
grids and negatively stained with 5% uranyl acetate. They contain
bundles of filamentous assemblies of diameter about 8-10 nm. The
framed area in (B) is shown in (C) at higher magnification. (D) The
filaments were decorated with 5-nm gold particles (arrows) by
immunogold labeling using an anti-a-Syn antibody, thus verifying
that they were assembled from a-Syn. Similar filamentous structures
were not detected in cultures without the SB treatment (data not
shown). Scale bar: 100 nm
Figure 6 The effect of SB exposure on a-Syn levels in TetOff-
induced cultures is minimal. One day after the seeding of 3D5
cells RA was added to the cultures to elicit differentiation for 10 ds.
Two subsets of these cultures were induced after 5 ds of
differentiation to express a-Syn for 5 ds. Another set was induced
after 1 d of differentiation to express a-Syn for 9 days. One set of
the 5 d-induced cultures was exposed to SB for 24 hs before cell
harvesting (labeled as SB-5D). Cultures with 5 and 9 ds of induced
a-Syn expression and without SB exposure are marked as Con-5D
and Con-9D, respectively. Cell lysates containing the same amount
of proteins from different samples derived from 3 independent
experiments were used for dot blotting with antibodies to a-Syn
and GAPDH, or Western blotting. Quantitative analyses were carried
out on dot blots to determine the ratio of a-Syn to GAPDH. When
the ratio derived from Con-5D dot blots was set as 1, the relative
amount of a-Syn to GAPDH is 0.97 ± 0.09 (average ± standard error
of mean) and 1.58 ± 0.06 for SB-5D and Con-9D preparations,
respectively. Based on Student’s t-test, there are no significant
differences (P > 0.8) between Con-5D and SB-5D. In comparison,
there are significant differences (P < 0.001) between Con-9D and
SB-5D or Con-5D. Since a-Syn oligomers were readily detected only
in SB-5D cultures, their production/accumulation is not caused by
an increase in the expression of a-Syn alone.
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salubrinal (Sal), which can counter oxidative stress [33],
lipid peroxidation [34], cytochrome C release [35] and
EIF2a dephosphorylation [36], respectively. Lysates from
these cultures were compared for a-Syn oligomer accu-
mulation. Among the agents tested, Sal was the only
one capable of preventing the SB-treated cells from both
apoptosis and accumulation of a-Syn aggregates (Figure
8); hence, ER stress response became the focus of our
subsequent studies. As reported before, Sal treatment
alone had no adverse effects on 3D5 cells.
To determine whether ER stress plays a role in a-Syn
oligomer accumulation, we used a known ER stress
inducer, tunicamycin (TM). Similar to SB-treated cells,
the TM-treated cultures displayed higher levels of a-Syn
oligomer than their non-treated counterparts (Figure
8B). Moreover, the increase was impeded by co-treat-
ment with Sal, thus establishing a close link between ER
stress and a-Syn oligomer accumulation.
To verify the effects of drug treatment on ER stress,
lysates from a-Syn expressing 3D5 cells (marked as a-
Syn+ in Figure 8), treated with or without SB, were
probed with antibodies to several markers relevant to
ER stress response (i.e. GRP78, p-EIF2a, XBP-1, ATF6a
and CHOP) and with antibodies to GAPDH to serve as
loading control (Figure 8B). The SB exposure caused an
increase in the ratio of p-EIF2a to total EIF2a and that
of CHOP and other ER stress markers to GAPDH
(Additional file 4, compared SB to Con). a-Syn+ cul-
tures co-treated with Sal and SB displayed lower levels
of CHOP (a molecule involved in ER stress-induced
apoptosis), XBP-1 (Additional file 4), but higher levels of
p-EIF2a and GRP78 when compared to the SB-treated.
The results are consistent with those reported pre-
viously, indicating that Sal is an inhibitor of EIF2a
dephosphorylation and that such inhibition leads to an
increase in molecular chaperones such as GRP78 and a
decrease in CHOP [37-39]. Studies of 3D5 cultures
exposed to other HDAC inhibitors (i.e. Agk2, VPA)
yielded comparable results (Additional files 5 &6).
Overexpression of a-Syn elicits ER stress response
Previous studies reported that induced expression of
A53T mutant a-Syn led to PC12 cell death and that the
toxicity is mediated via ER stress and mitochondrial cell
death pathways [40]. However, it was unknown whether
induced expression of wild-type a-Syn in 3D5 cells also
elicits an ER stress response. We investigated this issue
by probing 3D5 cell lysates with or without induced a-
Syn expression for ER stress markers. The induced cul-
tures (a-Syn+) displayed a higher ratio of either GRP78
to GAPDH or p-EIF2a to total EIF2a than their non-
induced (a-Syn-) counterparts, indicating the overex-
pression of wild-type a-Syn per se can cause an ER
stress response (Figure 8B & Additional file 4). It is
worth noting that without drug treatment neither a-
Syn- nor a-Syn+ cultures had detectable amounts of
CHOP, XBP-1 or ATF6a.
Induced expression of a-Syn sensitizes 3D5 cultures to SB
or TM toxicity via ER stress response
Cultures from a-Syn+ and a-Syn- were either treated
with SB, TM or not for 36 hrs followed by cell viability
assay (Figure 8A). At this time point cell death occurred
in both cultures with drug treatment. The drug expo-
sure significantly caused more cell loss in the a-Syn+
cultures than their a-Syn- counterparts. This difference
in drug response was significantly reduced in cultures
exposed to SB plus Sal or to TM plus Sal.
Similar to what we observed in a-Syn+ cultures, expo-
sure of a-Syn- cultures to SB, VPA, Agk2 or TM caused
an increase in ER stress response (Figure 8B, Additional
files 4 &5). However, the drug treatment was less
Figure 7 Pan-capase inhibitor treatment reduces the effect of
SB on apoptosis but not a-Syn oligomer accumulation. 3D5
cells with 10 ds of differentiation and induced a-Syn expression
were treated with 10 mM SB in the presence or absence of 50 μM
z-VAD (OMe)-fmk, a pan caspase inhibitor (CI), for 24 hs. Cultures
without any drug treatment or treated with CI only were included
as controls. (A) Calcein AM cell viability assay. The SB-treated
cultures displayed a significant decrease of cell viability when
compared to untreated counterparts (**P < 0.01, n = 3). The extent
of cell death is significantly reduced (#P < 0.05, n = 3) in cultures
treated with SB plus CI. (B) Western blotting of cell lysates.
Antibodies to a-Syn, caspase 9, active Caspase 3, PARP and GAPDH
were used. The SB and CI co-treated or the SB-treated cultures
displayed similar levels and profiles of a-Syn oligomers and
contained more a-Syn oligomers than non-treated (Con) or CI-
treated control. In contrast, the SB and CI co-treated cultures
displayed more full-length and less cleaved caspases 3 and 9 or
PARP than the SB-treated. Molecular weight markers were included
as references.
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Page 8 of 16Figure 8 Association of a-Syn oligomer accumulation with ER stress response. Differentiated 3D5 cells with (a-Syn +) or without (a-Syn -)
induced a-Syn expression were treated with 10 mM SB (10 mM), 40 μM salubrinal (Sal, an inhibitor of EIF2a dephosphorylation), 10 μg/ml
tunicamycin (TM, an ER stress inducer), SB plus Sal (SBSal) or TM plus Sal (TMSal) for 36 hs. Cells without any drug treatment served as controls.
(A) Cell viability. Significant differences were detected between drug treated and non-treated cultures [*P < 0.05 (e.g. SB/a-Syn + vs. Con/a-Syn
+, SB/a-Syn - vs. Con/a-Syn -)], between drug treated a-Syn + and a-Syn- cultures [#P < 0.05 (e.g. SB/a-Syn + vs. SB/a-Syn -)] or between SB (or
TM) and SB (or TM) plus Sal treated cultures [#P < 0.05 (e.g. SB/a-Syn + vs. SBSal/a-Syn +, TM/a-Syn + vs. TMSal/a-Syn +)]. (B) Western blotting.
Samples from cultures with different treatments were probed with antibodies to a-Syn, six markers of ER stress, active caspase 3 and GAPDH.
Exposure of a-Syn+ cultures to SB or TM promoted accumulation of a-Syn oligomers and expression of most ER stress markers. The presence of
Sal, however, inhibited this effect (i.e. SB versus SBSal, or TM versus TMSal). Similar drug exposure affected the ER stress response less in a-Syn-
cultures than in a-Syn+ cultures.
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and activation of caspase 3 in a-Syn- than a-Syn+ cul-
tures. Together, the results indicate that a-Syn overex-
pression elicits ER stress response leading to the
sensitization of 3D5 cultures to insults.
a-Syn- cultures co-treated with Sal and SB or other
aforementioned agents also led to increase in the level
of EIF2a phosphorylation and that of GRP78. However,
the amount of ATF6 was not affected. The result is con-
sistent with a recent report in which Sal treatment did
not affect ATF6 ER stress pathway [41].
ER stress response, a-Syn aggregation and apoptosis in
primary neuronal cultures exposed to SB and other HDAC
inhibitors
To determine whether the effects of HDAC inhibitors
treatment on a-Syn aggregation and ER stress response
are unique to 3D5 cultures, we next compared primary
cultures from a-Syn PAC mice (also referred to as TG
mice) to those of non-transgenic (NT) littermates for
their responses to the drug exposure, focusing first on
cell viability. The TG mice expressed low levels of wild-
type human a-Syn and did not have a-Syn aggregates
or neurodegeneration at any age (up to 24 months).
Cultures from both TG and NT mice had similar cell
numbers before their exposure to the drug. After 2 ds
of SB exposure (Figure 9A), significant cell loss was
demonstrated in TG cultures whereas such cell loss in
NT cultures was detected after 4 ds of drug treatment
(Figure 9B). In comparison, a significant cell loss was
observed after 24 hrs of the drug exposure in SB-treated
3D5 cultures. Consistent with what we observed in 3D5
cultures, co-treatment with Sal significantly protected
primary neuronal cultures from the cytotoxicity of SB
(Figure 9) or Agk2 (Additional file 7).
Overexpression of a-Syn in TG specimen was con-
firmed by Western blot analysis of cell lysates from pri-
mary cultures. The level of a-Syn monomers in TG
cultures is about 1.6 times of that detected in NT con-
trols (Figure 10, compared lanes 1 and 5). In the
absence of SB exposure, a-Syn oligomers were not read-
ily detected in TG or NT cultures. Upon SB treatment,
both cultures accumulated a- S y no fas i z ec o n s i s t e n t
with that of dimer (i.e. ~34 kDa), but the amount
appeared to be greater for the TG cultures. The increase
in a-Syn dimer did not result in the generation of inclu-
sions detectable by immunocytochemical staining with
a-Syn antibodies or Thioflavin S labeling. Co-treatment
of primary cultures with SB and Sal resulted in reduced
level of a-Syn dimers. The results are consistent with
those demonstrated in 3D5 cultures.
Treatment of primary neuronal cultures with SB also
resulted in an ER stress response and activation of cas-
pase 3 (Figure 10). Importantly, such response was more
intense in the SB-treated TG cultures than similarly
treated NT controls and less intense with Sal co-treat-
ment (Additional file 8).
Discussion
Many studies have been devoted to identifying the
mechanisms involved in a-Syn assembly and determine
whether the accumulation of a-Syn assemblies is cyto-
toxic or protective. Although the results are far from
conclusive, it is reasonable to suggest that the physico-
chemical property of a-Syn oligomers determines
Figure 9 Effects of SB and salubrinal on the survival of primary
neuronal cultures. Primary neuronal cultures from TG and NT mice
were exposed to 10 mM SB, 20 μM Sal, SB plus Sal for (A) 2 days
and (B) 4 days, Non-treated counterparts were included as controls
(Con). Without any drug treatment, cultures from TG and NT mice
have a similar number of cells. A 2-d treatment of cultures with SB
did not affect the survival of NT cultures, but resulted in a
significant (*P < 0.05) cell loss in TG cultures when compared to
untreated counterparts. The effect of SB on TG cell survival was
significantly (#P < 0.05) blocked by co-treatment with Sal. Cell loss
was noted in NT cultures treated with SB for 4 ds (**P < 0.01), but
the extent of such change is significantly (#P < 0.05) less than that
demonstrated in TG cultures with same duration of SB treatment.
Co-treatment with Sal also reduced the cell loss caused by a 4d
exposure to SB.
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tant cytotoxicity has to aggregate formation. In this
regard, the 3D5 transfectant is of great value for identifi-
cation of pathways that modulate the risk of a-Syn-
mediated cytotoxicity and agents capable of inhibiting
accumulation of a-Syn and its assemblies, due to its
ability to accumulate a-Syn assemblies without compro-
mising cell survival [14].
A number of agents have been tested in previous cell-
based studies and shown to reduce a-Syn aggregation
and its toxicity [11,12,42,43]. In the present study, we
investigated the effect of SB, Val or Agk2 treatment on
a-Syn assembly/accumulation in 3D5 cultures. We
demonstrated that exposure to each of these drugs
reduced the viability of differentiated, a-Syn induced
3D5 cells and enhanced a-Syn oligomer accumulation,
and that overexpression of wild-type a-Syn alone is not
cytotoxic. This is in contrast to what was observed in
previous studies [12], in which overexpression of a-Syn
in the nuclei, but not cytoplasm, of neuroblastoma cells,
SH-SY5Y, resulted in cell death. Treatment of SH-SY5Y
cultures with 10 mM SB for 48 hs was shown to protect
cells from toxicity caused by nuclear accumulation of a-
Syn, but did not adversely affect those with cytoplasmic
a-Syn accumulation. Treatment of H4 cells overexpres-
sing A53T a-Syn with Agk2 was shown to reduce cell
death caused by cytoplasmic a-Syn aggregates. In con-
trast, treatment of a-Syn overexpressing 3D5 cells with
Agk2 caused cell death. The discrepancy may reflect dif-
ferences in cell type, as supported by the results from
our analysis of non-induced 3D5 cultures and non-
transfected SH-SY5Y cells (Additional file 9). Cell death
w a sn o t e di n3 D 5c u l t u r e sw i t h i n2 4h so fS B( 1 0m M )
treatment. In comparison, cell death was not observed
up to 48 hrs after treatment of SH-SY5Y cells, indicating
they are less sensitive than 3D5 cells to SB cytotoxicity.
Therefore, to evaluate whether drug treatment has bene-
ficial effects or not in cell-based studies, it is important
to examine more than one cell type. For this reason, we
included primary neuronal cultures in the present stu-
dies. This also allowed us to substantiate the pathobiolo-
gical relevance of findings from cell-line based studies.
We showed that exposing 3D5 and primary cultures
to HDAC inhibitors caused an accumulation of a-Syn
oligomers, an increase in ER stress response and a
decrease in cell survival. In this regard, several recent
studies have demonstrated the induction of ER stress
response in cell cultures following treatment with differ-
ent HDAC inhibitors [30-32]. In our studies, such stress
response was greater for cultures with a-Syn overex-
pression than those without. We considered that the dif-
ference is at least in part, if not entirely, due to
differences in the basal level of ER stress markers. This
is in light of our results that (i) a-Syn overexpression
alone, regardless of whether it led to the assembly of
filamentous a-Syn [14] or not, elicited ER stress
response, (ii) inhibition of EIF2a dephosphorylation via
Sal treatment protected cultures from undergoing apop-
tosis caused by HDAC inhibitors exposure, (iii) treat-
ment of cultures with ER stress inducer TM also
resulted in a-Syn oligomer accumulation as in the
HDAC inhibitors treated, and (iv) such accumulation
was reduced by co-treatment of cultures with Sal. It has
been reported that overexpression of A53T mutant a-
Syn or wild-type a-Syn phosphorylated at serine 129
caused ER stress and cell death in PC12 or SH-SY5Y
cells [40,44], and that expression of human a-Syn in
yeast cells led to blocking of ER-Golgi traffic [45].
Recently, induced a-Syn expression was shown to
increase the vulnerability of PC12 cells to stressors such
as thapsigargin, TM and 1-methyl-4-phenyl-pyrisinium
( M P P + )[ 4 6 ] .W ea l s oh a v ed a t ad e m o n s t r a t i n gd i f f e r -
ences between the induced and non-induced 3D5
Figure 10 SB and Sal exposure of primary neuronal cultures
affects ER stress response, apoptosis and a-Syn aggregation.
Primary neuronal cells from TG and NT mice, after 7 days in
cultures, were treated with 10 mM SB or SB plus 20 μM Sal for 96
hs. Non-treated counterparts were included as controls (Con).
Proteins extracted from different cultures were evaluated by
Western blotting using antibodies to five ER stress markers, active
caspase 3, a-Syn and GAPDH. Cells from TG mice expressed about
1.6 times (normalized to GAPDH) more a-Syn than those from NT
controls. The SB-treated TG and NT cultures (TGSB & NTSB)
expressed more abundant ER stress markers than their controls, and
such stress response and caspase 3 activation are greater for the TG
than NT cultures. These changes were reduced in cultures treated
with SB plus Sal. The results are consistent with those obtained
from the 3D5 cell line, which expresses higher a-Syn than primary
neuronal cultures.
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+, rotenone, 6-hydroxydopamine(6-OHDA), paraquat)
(Additional file 10). Other investigators have also pro-
vided evidence supporting the important role of ER
stress response in PD pathogenesis. For example: (i)
activation of ER stress response was detected in dopami-
nergic neurons in the substantia nigra of postmortem
PD cases [47], and (ii) PD animal or cell models gener-
ated via exposure to neurotoxins displayed ER stress
response [48,49].
We do not know how HDAC inhibitor treatment
leads to ER stress in neuronal cells. However, recent
studies of non-neuronal cells demonstrated that (i)
exposure of breast cancer cells to panobinostat (a pan
HDAC inhibitor) led to deacetylation of GRP78, disso-
ciation of GRP78 from PERK and increase the levels of
pEIF2a, ATF4 and CHOP [32], (ii) exposure of colorec-
tal carcinoma cells to tricostatin A (a pan-HDAC inhibi-
tor) affected the binding of HDAC to GRP78 promotor
[30] and (iii) the C-terminal region of RTN-C protein,
an ER membrane protein, can interact with HDAC8 in
vitro [50].
Our studies showed that 3D5 and primary cultures
have different sensitivities to HDAC inhibitor treatment.
When the same dosage of SB or VPA was used to treat
these cultures, it required a longer duration of incuba-
tion for primary cultures to display cytotoxicity. In con-
trast, 3D5 cells were less sensitive than primary cultures
to Agk2 exposure. The cause(s) of such differences in
drug sensitivity remains unknown. We noted that a pre-
vious study has demonstrated a protective effect of
Agk2 treatment on rat primary neuronal cultures over-
expressing A53T a-Syn via lentiviral infection of con-
structs containing mutant a-Syn [11]. The discrepancy
between the previous study and our primary neuronal
culture study may be due to differences in experimental
paradigm. Low levels of overexpressing wild-type human
a-Syn in mice had no impact on the viability of mouse
primary neuronal cultures. In comparison, overexpres-
sion of A53T a-Syn by viral infection reduced cell
survival.
We showed that 3D5 and primary cultures treated
with HDAC inhibitors have different quantity/quality of
a-Syn oligomers. Most a-Syn oligomers appearing in
primary neuronal cultures are dimers and relatively
soluble, whereas those in 3D5 cells are larger oligomers
with different solubility (ranging from buffer-extractable
to sarkosyl-insoluble). The distinction may reflect differ-
ence in a-Syn expression levels. This is supported by
our findings that the level of a-Syn in TetOff induced
3D5 cells is far greater than that expressed in primary
neuronal cultures from TG mice (based on equal sample
loading (Additional file 11). Moreover, it has been
reported that a critical concentration of a-Syn is
required to initiate a-Syn assembly in test tubes, and
that formation of dimer is an early step of a-Syn assem-
bly [51]. The difference between cell types in a-Syn oli-
gomers production may also reflect the rate of a-Syn
assembly. In this regard, several molecules have been
shown to promote a-Syn assembly in vitro and in vivo
[52-56]. It is possible that the amount/type of endogen-
ous inducer for a- S y na s s e m b l ym a yv a r yi nd i f f e r e n t
cell types.
Our finding that an overexpression of wild-type
human a-Syn in both 3D5 and primary cultures can eli-
cit ER stress response is noteworthy. According to some
studies, the accumulation of a-Syn in the human brain
elevates significantly during aging [57,58]. There is also
ample evidence that the unfold protein response is com-
promised with aging [59]. Therefore, there is a potential
risk of using HDAC inhibitors as therapeutics for elderly
subjects with neurodegenerative disorders [60].
Materials and methods
Conditional transfectant 3D5
Alpha-Syn transfectant 3D5 was derived from a human
neuroblastoma cell line (BE2-M17D) and characterized
previously [13,14]. The transfectant expresses wild-type
human a-Syn and displays neuronal phenotypes upon
TetOff induction and incubation with RA [14]. Cultures
of 3D5 were maintained in DMEM/10% fetal bovine
serum with 2 μg/mL Tet (referred to as non-induced or
a-Syn-) or without (referred to as induced or a-Syn+)
at 37°C and 5% CO2. Those intended for biochemical
analysis were seeded at 0.5 × 10
6 cells/plate (100 × 20
mm, BD Biosciences, San Jose, CA) or 1.5 × 10
5 cells/
well in 6-well plates. For immunofluorescence or spec-
trophotometric assay, 3D5 cells were seeded at 2 × 10
4
cells/well on coverslips in 24-well plates and 1 × 10
4 in
48-well plates (Bellco Glass Inc, Vineland, NJ), respec-
tively. Media were replaced the next day with Neuroba-
sal medium (Invitrogen, Carlsbad, CA), 2% B-27
supplement (antioxidant free, Invitrogen), 2 mM L-glu-
tamine (Sigma) and 10 μM RA (Sigma-Aldrich, St Louis,
MO). After 10 ds of differentiation and induced a-Syn
overexpession, cells were treated with HDAC inhibitors
[SB (sigma), VPA (Sigma) and Agk2 (EMD Biosciences,
La Jolla, CA)], a derivative of short-chain fatty acid
[sodium acetate (SA)], an endoplasmic reticulum (ER)
stress inducer [tunicamycin (TM, Sigma)], an inhibitor
of phosphatases that act on the eukaryotic translation
factor 2 subunit alpha (EIF2a) [salubrinal (Sal, Tocris
Bioscience, Ellisville, Missouri)], a protein synthesis inhi-
bitor [cycoheximide (CHX, Sigma), or a pan caspase
inhibitor (CI) [Z-VAD (OMe)-FMK (EMD Biosciences)].
The cultures were treated with different drug concentra-
tions for durations described in the Result section. Some
cultures were treated with two of the aforementioned
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a-Syn induction).
Primary neuronal cultures were prepared from hippo-
campal and cortical brain tissues of postnatal (day 1) mice
(see below) with or without transgenic expression of wild-
type human a-Syn, according to a protocol reported
previously [61]. They were plated at 6 ~ 7 × 10
5 cells per
well on poly-D-lysine (Sigma) coated 6-well plate and
maintained for 7 ds before treatment in the absence or
presence of different drugs for different durations.
Animals
All animal procedures were approved by the Mayo
Clinic Institutional Animal Care and Use Committee
(IACUC) and were in accordance with the National
I n s t i t u t eo fH e a l t hG u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals (NIH Publications No. 80-23)
revised 1996.
Alpha-Syn PAC transgenic mice
Mice were provided by Dr. Farrer’s Laboratory and will
be described in detail elsewhere. Briefly, transgenic mice
were generated using a P1 artificial Chromosome (PAC)
RP-1 27 M07, which was previously identified to contain
t h ee n t i r ew i l d - t y p eh u m a na-Syn gene and regulatory
sequences PAC DNA [62]. Purified DNA was injected
into FVB/N (Taconic, Germantown, NY) fertilized
oocytes and transplanted into pseudo-pregnant ICR
(Harlan, Indianapolis, IN) female mice. Transgenic foun-
ders were genotyped by PCR and analyzed for gene
expression by quantitative RT-PCR and western blotting.
The founder line with the highest expression was
expanded and maintained on FVB/N background (Taco-
nic). Human protein expression in 6 month-old mice is
approximately 2 fold of endogenous murine a-Syn. The
expression level is highest in the hippocampus followed
by cortex, olfactory tubercle and striatum.
Antibodies
To detect a-Syn, we used monoclonal antibody Synu-
clein-1 (BD Biosciences) and polyclonal antibody Ab98
[63]. For other proteins we used rabbit polyclonal anti-
bodies to total and cleaved Caspase-3, Caspase 9 and
PARP (Cell Signaling, Danvers, MA), phosphorylated
EIF2a (pEIF2a, Invitrogen), GADD153/CHOP10
(Sigma), XBP-1 and ATF6a (Santa Cruz Biotechnology,
Santa Cruz, CA). We also used monoclonal antibodies
to GRP78 (BD Biosciences), total EIF2a (T-EIF2a,C e l l
Signaling) and GAPDH (1D4, Covance Research Pro-
ducts, Berkeley, CA). The binding of primary antibody
to protein of interest was detected using peroxidase-
c o n j u g a t e dg o a ta n t i - r a b b i to ra n t i - m o u s eI g Ga n t i b o -
dies (Chemicon, Temecula, CA) and Alexa594 or
Alexa488 goat anti-mouse antibodies (Invitrogen).
Western blot analysis
Cell cultures were harvested and centrifuged at 200 × g
for 15 min. The pellet was resuspended in a lysis buffer
[ 2 0m MM E S ,p H6 . 8 ;8 0m MN a C l ,1m MM g C l 2,2
mM EGTA, 10 mM NaH2PO4,2 0m MN a F ,p h e n y l -
methylsulfonyl fluoride (PMSF, 1 μg/ml and leupeptin,
10 μg/mL], homogenized and centrifuged at 180 × g for
15 min at 4°C. The cell lystates were mixed with Tri-
cine-SDS sample buffer (Invitrogen) and 2% b-mercap-
toethanol, boiled for 5 min and resolved by SDS-PAGE
using 10-20% Tris/Tricine gel (Bio-rad, Hercules, CA).
Precision plus protein standards (Bio-Rad) were
included as references. Proteins separated by SDS-PAGE
were transferred onto nitrocellulose and processed for
immunolabeling for proteins of interest. Membranes
probed with GAPDH antibody were used as loading
controls. Immunoreactivity was visualized with
enhanced chemiluminescence (ECL plus, Amersham
Pharmacia Biotech, Buckinghamshire, UK) or Super-
Signal West Femto Maximum Sensitivity Substrate
(Thermo Scientific, Rockford, IL) and analyzed as before
[64].
Fractionation Studies of Culture Specimens
Cell lysates were fractionated to derive buffer extractable
(SN1), 5 M NaCl/1% sarkosyl-soluble (SN2) and 1% sar-
kosyl-insoluble fractions (SKI) as reported [14]. The SKI
fraction was finally resuspended in 50 mM Tris (pH
8.0). All fractions and lysates were analyzed by Western
blotting. A portion of the SKI sample from TetOff
induced cultures with or without SB treatment and cor-
responding sample from cultures without a-Syn induc-
tion were analyzed further (see below).
Electron and immunoelectron microscopies
Sakosyl-insoluble samples were processed for electron
and immunoelectron microscopies using protocols
described previously [64]. Cultures with or without SB
treatment were processed as before [14] for electron
microscopy.
Immunocytochemistry
Cells grown on coverslips were rinsed with PBS, fixed in
4% paraformaldehyde and permeabilized with 0.1 M
Tris-buffered saline (TBS, pH 7.6) containing 0.5% triton
X-100 for 5 min. They were subsequently blocked with
3% goat serum in TBS, incubated with antibody Synu-
clein-1 in TBS containing 1% goat serum overnight at
4°C then incubated with Alexa594 goat anti-mouse sec-
ondary antibody for 1 h. For Thioflavin S staining the
coverslips were immersed in 0.0005% thioflavin S/PBS/
formalin and washed 3 times with 70% ethanol and
TBS. After immuno- and thiofavin S staining, the cover-
slips were stained with DAPI (Invitrogen) for 10 min to
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microscopy (Zeiss LSM 510; Carl Zeiss MicroImaging,
Thornwood, NY).
Cell viability
The viability of 3D5 cells was assessed by incubation of
cultures with 2 μM calcein AM (Invitrogen), according
to the manufacturer’s recommendation. Fluorescence
emitted from live cells was measured at 495 nm (excita-
tion)/530 nm (emission) using a Cary Eclipse Fluorom-
eter and Spectra Max M2 and Soft Max Protein 4.6
software (Molecular Devices, Sunnyvale, CA). All mea-
surements were performed in triplicate. Viability of pri-
mary neuronal cultures was assessed by counting cells
in live cultures. We randomly captured the image of
cultures at 10-15 fields (200×). Each image was evalu-
ated independently by two-individuals for intact cells to
derive the number of cells in all fields as well as the
average cell counts per field. After image capturing, the
cultures were processed for Western blot analysis.
Statistical analysis
Data from at least 3 sets of independent experiments
were analyzed by one-way Anova with Dunnett’s post
hoc test or Student’s t test to determine statistical
significance.
Additional material
Additional file 1: Effects of Agk2 and VPA exposure on a-Syn
oligomerization and caspase 3 activation. 3D5 cells with 10 days (ds)
of RA elicited differentiation and TetOff-induced a-Syn expression were
exposed to Agk2 (21 μM) and VPA (10 mM) for 18 and 36 hours (hs).
Cultures without the drug treatment for 36 hs were used as controls
(Con). Proteins from these cultures were resolved by SDS-PAGE and
probed with antibodies to a-Syn, GAPDH and active caspase 3. The Agk2
and VPA treated cells contained more a-Syn oligomers (34 to 230 kDa in
size) and cleaved caspase 3 than non-treated counterparts. The results
are similar to those obtained from cultures treated with sodium butyrate.
Molecular weight markers shown in current or subsequent figures were
used to calibrate the size of a-Syn products. Asterisk marks monomeric
a-Syn.
Additional file 2: Distinct differences between sodium acetate (SA)
and sodium butyrate (SB) exposure on a-Syn oligomerization. 3D5
cells with 10 days (ds) of RA elicited differentiation and TetOff-induced
a-Syn expression were treated with SA (20 mM), SB (10 mM) or no drugs
(Con) for 24 hs. Proteins from lysates of these cultures were resolved by
SDS-PAGE and probed with antibodies to a-Syn and GAPDH. In contrast
to that demonstrated in the SB-treated cultures, SA treatment did not
lead to an increase of a-Syn oligomers. Asterisk marks monomeric a-Syn.
Additional file 3: Inhibition of a-Syn expression at the transcription
or translation level minimally affected SB induced a-Syn
aggregation in 3D5 cells with 10 ds of differentiation and induced
a-Syn expression. Cultures were exposed to SB (10 mM), SB plus 2 μg/
ml Tet (to block a-Syn induction) or SB plus cycloheximide (CHX, 20 μM,
to inhibit protein synthesis) for 36 hs. Cultures without any drug
treatment or treated with Tet or CHX only were included as controls. Cell
lysates were probed with antibodies to a-Syn and GAPDH. Cultures co-
treated with SB and Tet or SB and CHX contained more a-Syn oligomers
than those without drug treatment or treated with Tet or CHX alone.
The co-treated cultures contained a-Syn oligomers slightly less than
those treated with SB, indicating the accumulation of a-Syn oligomers in
SB-treated cells is unlikely caused by an increase of a-Syn expression.
Additional file 4: Quantification of Western blot shown in Figure 8
Additional file 5: Effects of VPA, Agk2 and co-treatment with Sal on
accumulation of a-Syn oligomers and expression of ER stress
markers. Differentiated 3D5 cells with induced a-Syn expression (a-Syn
+) or without the induction (a-Syn-) were treated with Sal (40 μM), VPA
(10 mM), VPA plus Sal (VPASal), Agk2 (21 μM) or Agk2 plus Sal (Agk2Sal)
for 24 hs. Cells without the drug treatment were included as controls
(Con). Western blotting demonstrated that VPA or Akg2 exposure leads
to a marked increase of a-Syn oligomers, ER stress markers CHOP and p-
EIF2a/T-EIF2a and a moderate increase of GRP78 in the a-Syn + cells.
Without any drug treatment, GRP78 was detected more in the a-Syn+
than the a-Syn- cultures.
Additional file 6: Quantification of Western blot shown in additional
file 5
Additional file 7: Survival of TG or NT primary neuronal cultures
exposed to Agk2, Sal and both. Primary cultures TG and NT mice were
treated with Agk2 (7 μM), Sal (20 μM) or Agk2 plus Sal (Agk2Sal) for 24
hs. TG cultures were more sensitive to Agk2 treatment than NT controls,
and co-treatment with Sal can protect cultures from Agk2 toxicity. *P <
0.05, compared TGCon to TGAgk2; #P < 0.05, compared TGAgk2Sal to
TGAgk2 or NTAgk2 to TGAgk2.
Additional file 8: Quantification of Western blot shown in Figure 10
Additional file 9: Differences between 3D5 and SH-SY5Y cells in
sensitivity to SB treatment. 3D5 and SH-SY5Y cells were seeded in 24
well plates at the same number per well. They were exposed to SB (10
mM) and assessed for cell viability after 24, 48 and 96 hs of the drug
exposure. Cultures without the drug treatment were included as controls
(Con).
Additional file 10: Differential effects of neurotoxin exposure on
the survival of 3D5 cells. Differentiated 3D5 cells with induced a-Syn
expression (a-Syn+) or without (a-Syn-), were treated with 6-OHDA (400
μM), MPP+ (3 mM), Paraquat (1.5 mM) and Rotenone (60 μM) for 30 hs,
then assessed for cell viability by Calcein AM assay. *P < 0.05, compared
between a-Syn + and a-Syn- cultures.
Additional file 11: Comparison of a-Syn expression level between
TG primary neurons and 3D5 cells. TG primary neuronal cultures as
well as RA-differentiated and TetOff induced 3D5 cells after 7 ds and 10
ds in cultures, respectively, were harvested. Subsequent to protein
extraction and quantification, equal amount of proteins from each
sample were resolved by SDS-PAGE and immunoblotted with antibody
for a-Syn. Results showed that 3D5 cells contain more a-Syn than
primary cultures.
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